Contraception in Systemic Lupus Erythematosus Patients

Safety and Recommendations

The American College of Rheumatology recommends levonorgestrel IUDs as a suitable contraceptive option for patients with Systemic Lupus Erythematosus (SLE), particularly when the benefits of reduced menstrual bleeding outweigh potential risks 1, 2
For SLE patients with inactive or stable disease, levonorgestrel IUDs are a highly effective and safe contraceptive option with minimal impact on disease activity 2
For SLE patients with moderate to severe disease activity, progestin-only methods like levonorgestrel IUDs are strongly recommended over combined estrogen-progestin contraceptives 2
The levonorgestrel IUD offers additional benefits for SLE patients on anticoagulation by reducing excessive menstrual bleeding 1

In SLE patients with positive antiphospholipid antibodies (aPL), levonorgestrel IUDs are strongly recommended as one of the preferred contraceptive methods 2
Combined estrogen-progestin contraceptives are contraindicated in SLE patients with positive aPL due to increased thrombosis risk 1, 2
For aPL-positive patients, both copper and levonorgestrel IUDs are suitable options, with levonorgestrel IUDs offering the additional benefit of reduced menstrual bleeding 2

Long-acting reversible contraception with high efficacy rates (pregnancy rates <1% per year) 2
Reduced menstrual blood loss, particularly beneficial for patients on anticoagulation therapy 1
Does not require daily adherence, making it ideal for patients on complex medication regimens 2

Avoid depot medroxyprogesterone acetate (DMPA) in SLE patients with positive aPL due to potential increased thrombosis risk 2, 3
Ensure SLE patients are tested for aPL before making contraceptive recommendations, as this significantly impacts contraceptive choice 3